Soleno Therapeutics saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 84 to 97.
IBD's unique rating identifies share price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
History shows that the market's biggest winners tend to have an RS Rating north of 80 at the beginning of a new price run.
Looking For The Best Stocks To Buy And Watch? Start Here
Soleno Therapeutics is now considered extended and out of buy range after clearing a 60.92 buy point in a fourth-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Soleno Therapeutics posted 0% earnings growth in its most recent report, while sales growth came in at 0%.
Soleno Therapeutics holds the No. 39 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
